SCHEMBL1691241

SCHEMBL1691241

OCc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.68
SLC2A1 P11166 5/20 0.63
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
GABRA2 P47869 1/20 0.61
GABRB2 P47870 1/20 0.61
KDM4E B2RXH2 1/20 0.60
HTT P42858 1/20 0.60
TSPO P30536 2/20 0.58
NR1I2 O75469 1/20 0.58
ABCB11 O95342 1/20 0.58
ALB P02768 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
ADORA1 P30542 1/20 0.58
OPRM1 P35372 1/20 0.58
DRD3 P35462 1/20 0.58
OPRK1 P41145 1/20 0.58
PDE4D Q08499 1/20 0.58
KCNH2 Q12809 1/20 0.58
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1692145 0.91 ALDH1A1 (0.58) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL1691321 0.90 ALDH1A1 (0.56) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL1691885 0.88 GABRB2 (0.55) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL1691376 0.88 ALDH1A1 (0.58) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL1691849 0.88 ALDH1A1 (0.58) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL17718900 0.87 SLC2A1 (0.71) SLC2A1
SCHEMBL1691861 0.85 SLC2A1 (0.65) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL10175208 0.85 GABRA2 (0.53) ALDH1A1SLC2A1MEN1KMT2AGABRA2
SCHEMBL1691322 0.85 ALDH1A1 (0.51) ALDH1A1SLC2A1MEN1KMT2AGABRA2
Hydrochloric Acid SCHEMBL1429987 0.84 ALDH1A1 (0.68) ALDH1A1SLC2A1MEN1KMT2AGABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP claimed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US claimed
EP-2376490-A1 IMIDAZOPYRIDINE COMPOUNDS Proximagen Limited (GB) 2011-10-19 EP claimed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO claimed
EP-3777846-A1 VAP-1 INHIBITORS FOR TREATING PAIN BenevolentAI Cambridge Limited (GB) 2021-02-17 EP disclosed
US-20200397764-A1 VAP-1 INHIBITORS FOR TREATING PAIN PROXIMAGEN, LLC 2020-12-24 US disclosed
WO-2017098236-A1 VAP-1 INHIBITORS FOR TREATING PAIN PROXIMAGEN LIMITED (GB) 2017-06-15 WO disclosed
US-20160113893-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS UPSHER-SMITH LABORATORIES, INC. 2016-04-28 US disclosed
US-20160113893-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS UPSHER-SMITH LABORATORIES, INC. 2016-04-28 US disclosed
US-20160101072-A1 Therapeutic uses of enzyme inhibitors PROXIMAGEN LIMITED (GB) 2016-04-14 US disclosed
US-20160101072-A1 Therapeutic uses of enzyme inhibitors PROXIMAGEN LIMITED (GB) 2016-04-14 US disclosed
WO-2015189534-A1 VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY PROXIMAGEN LIMITED (GB) 2015-12-17 WO disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
EP-2376490-A1 IMIDAZOPYRIDINE COMPOUNDS Proximagen Limited (GB) 2011-10-19 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200397764-A1 VAP-1 INHIBITORS FOR TREATING PAIN VAPB, VAPA, OPRL1 ALDH1A1 477/4885SLC2A1 2866/4885MEN1 4777/4885
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 ALDH1A1 65/4885SLC2A1 1801/4885MEN1 3221/4885
US-20160113893-A1 NEW THERAPEUTIC USES OF ENZYME INHIBITORS VAPB, VAPA, AOX1 ALDH1A1 289/4885SLC2A1 1772/4885MEN1 4747/4885
US-20160101072-A1 Therapeutic uses of enzyme inhibitors VAPB, VAPA, AOX1 ALDH1A1 201/4885SLC2A1 1743/4885MEN1 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.